Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.68 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | AXL | P30530 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL29488713 | 0.94 | IRAK4 (0.62) | IRAK4SMPD3HTTHSD11B1SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL20483266 | 0.90 | IRAK4 (0.58) | IRAK4SMPD3HTTHSD11B1SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL29487606 | 0.90 | IRAK4 (0.58) | IRAK4SMPD3HTTHSD11B1SMN1; SMN2 | |
| SCHEMBL309036 | 0.86 | IRAK4 (0.58) | IRAK4SMPD3HTTHSD11B1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30152392 | 0.84 | IRAK4 (0.57) | IRAK4SMPD3HTTHSD11B1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL31474423 | 0.84 | IRAK4 (0.57) | IRAK4SMPD3HTTHSD11B1SMN1; SMN2 | |
| SCHEMBL10042194 | 0.83 | HTT (0.58) | IRAK4SMPD3HTTHSD11B1SMN1; SMN2 | |
| SCHEMBL309358 | 0.83 | HSD11B1 (0.57) | IRAK4SMPD3HTTHSD11B1SMN1; SMN2 | |
| SCHEMBL30798592 | 0.83 | SMPD3 (0.56) | IRAK4SMPD3HTTHSD11B1SMN1; SMN2 | |
| SCHEMBL18048147 | 0.82 | IRAK4 (1.00) | IRAK4HTTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745138-A1 | THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| CN-120202200-A | Oxo-isoindolinyl substituted tetrahydropyrimidinedione-based compounds and applications thereof | 标新生物医药科技(上海)有限公司 | 2025-06-24 | — | — | CN | claimed |
| EP-3856251-B1 | COMBINATION OF A PD-1 ANTAGONIST, AN ATR INHIBITOR AND A PLATINATING AGENT FOR THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2024-10-09 | — | — | EP | claimed |
| EP-3840832-B1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BENEVOLENTAI BIO LTD (GB) | 2023-10-11 | — | — | EP | claimed |
| CN-116867494-A | IRAK4 degrading agent and use thereof | 凯麦拉医疗公司 | 2023-10-10 | — | — | CN | claimed |
| CN-116847842-A | IRAK4 degrading agent and use thereof | 凯麦拉医疗公司 | 2023-10-03 | — | — | CN | claimed |
| EP-2903978-B1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | claimed |
| EP-4086259-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2022-11-09 | — | — | EP | claimed |
| EP-3268367-B1 | CARBOXAMIDE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2022-10-05 | — | — | EP | claimed |
| EP-4017856-A1 | PHARMACEUTICAL COMPOUNDS | Reviral Limited (GB) | 2022-06-29 | — | — | EP | claimed |
| EP-3371190-B1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2022-03-30 | — | — | EP | claimed |
| EP-2802590-B1 | THIENOPYRIMIDINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-03-01 | — | — | EP | claimed |
| US-20140194404-A1 | AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES | MERCK SHARP & DOHME LLC | 2014-07-10 | — | — | US | claimed |
| EP-2688872-A1 | AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES | Merck Sharp & Dohme Corp. (US) | 2014-01-29 | — | — | EP | claimed |
| WO-2012129258-A1 | AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES | MERCK SHARP & DOHME CORP. (US) | 2012-09-27 | — | — | WO | claimed |
| US-7378417-B2 | Pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-27 | — | — | US | claimed |
| EP-1761541-B1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | claimed |
| EP-1761541-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | claimed |
| WO-2005123738-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | WO | claimed |
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | P2RX3, P2RX1, P2RX5 | IRAK4 480/4885SMPD3 2724/4885HTT 2091/4885 |
| US-20140194404-A1 | AMIDOPYRAZOLE INHIBITORS OF INTERLEUKIN RECEPTOR-ASSOCIATED KINASES | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885SMPD3 3854/4885HTT 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.